Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Current Breast Cancer Reports

, Volume 5, Issue 2, pp 86-98

First online:

New Treatment Paradigms for Patients with Ductal Carcinoma In Situ

  • Aimee MackeyAffiliated withDepartment of Surgery, Duke University Medical Center
  • , Rachel GreenupAffiliated withDepartment of Surgery, Duke University Medical Center
  • , E. Shelley HwangAffiliated withDepartment of Surgery, Duke University Medical Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


One of the most poorly understood clinical diagnoses in breast cancer is ductal carcinoma in situ (DCIS), which now accounts for almost one third of all mammographically detected malignancies. Detection and diagnosis of DCIS have improved, and mature data from randomized controlled trials of lumpectomy for DCIS have provided some measure of the magnitude of benefit to be derived from adjuvant treatments. The past 5 years have seen the emergence of molecular prognostic tools, which together with clinical factors have the potential to allow better selection of individualized therapies for these heterogeneous lesions. Ongoing and future research to identify which patients with DCIS can be safely managed with active surveillance are underway and will create opportunities to better understand the biology of this disease, thereby informing treatment strategies that are more closely aligned with the invasive potential of specific DCIS subtypes.


Ductal carcinoma in situ DCIS Breast cancer Mammography MRI Mastectomy Lumpectomy Radiation Sentinel lymph node biopsy Systemic therapy Prognosis Biomarkers Preoperative hormone therapy Her-2 directed therapies Active surveillance